Eptinezumab
Eptinezumab Uses, Dosage, Side Effects, Food Interaction and all others data.
Eptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (Pichia pastoris) and developed by Lundbeck Seattle Biopharmaceuticals. Eptinezumab has been specifically designed to bind to both alpha and beta forms of the human calcitonin gene-related peptide (CGRP). It was approved by the FDA in February 2020 for the preventive treatment of migraine headaches in adults.
["EconoTimes Business Article: Alder BioPharmaceuticals\u00ae New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals (Up to 32.5 days) and Improved Quality-of-Life Outcomes in Patients with Episodic Migraine\" href=\"#reference-L2825","6 Moreover, a post hoc analysis revealed that those patients achieving a 75% or greater response rate had over an eight-fold increase in days between migraines.\n"] ["EconoTimes Business Article: Alder BioPharmaceuticals\u00ae New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals (Up to 32.5 days) and Improved Quality-of-Life Outcomes in Patients with Episodic Migraine\" href=\"#reference-L2825","6 Moreover, a post hoc analysis revealed that those patients achieving a 75% or greater response rate had over an eight-fold increase in days between migraines.\n"]
| Trade Name | Eptinezumab |
| Availability | Prescription only |
| Generic | Eptinezumab |
| Eptinezumab Other Names | Eptinezumab |
| Related Drugs | propranolol, atenolol, topiramate, nifedipine, Depakote, verapamil |
| Weight | 100mg/ml |
| Type | Intravenous solution |
| Weight | 143000.0 Da |
| Protein binding | Readily accessible data regarding the protein binding of eptinezumab is not available. |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | United States |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Eptinezumab is a monoclonal antibody directed against CGRP infused every 3 months for the preventive treatment of migraine in adults.
Eptinezumab is indicated for the preventive treatment of migraine in adults.
Eptinezumab is also used to associated treatment for these conditions: Migraine
How Eptinezumab works
Eptinezumab is a fully-humanized IgG1 antibody manufactured and designed specifically to bind both alpha and beta forms of the human calcitonin gene-related peptide (CGRP).
Studies since 1985 have demonstrated that CGRP levels increase during acute migraine attacks in migraine-suffering patients but normalize after efficacious sumatriptan therapy. Moreover, research has also shown that intravenous administration of CGRP can induce migraine-like attacks in migraine-suffering patients. For all these reasons, the binding of CGRP to interfere with its activity was specifically designed to be the form and mechanism of action for eptinezumab. The binding of eptinezumab to natural endogenous CGRP subsequently interferes with its activities, such as its binding to CGRP receptors, for example.
Toxicity
The most frequent adverse events associated with eptinezumab use include upper respiratory tract infection, urinary tract infection, fatigue, back pain, arthralgia, and nausea and vomiting . No data regarding overdosage has been reported yet.
Food Interaction
No interactions found.Volume of Distribution
The central volume of distribution for eptinezumab is approximately 3.7 L.
Elimination Route
Eptinezumab is the only potent and selective and anti-calcitonin gene-related peptide (CGRP) monoclonal antibody administered by quarterly infusion for migraine prevention delivering 100% bioavailability by way of the intravenous route of administration to immediately inhibit CGRP .
With an intravenous dose of eptinezumab 1000 mg, the mean maximum concentration of 336.4 ug/mL (SD 79.9) occurred after 4.8 hours after the start of the 1 hour infusion . The mean exposure to free eptinezumab, as characterized by area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration and from time zero to infinity were 8245 days per ug per mL (SD 2619) and 8722 days per ug per mL (SD 2522), respectively .
Half Life
The plasma half-life after an intravenous infusion is approximately 27 days.
Clearance
The apparent clearance of eptinezumab is 0.006 L/h.
Elimination Route
Monoclonal antibody agents like eptinezumab are generally not eliminated via hepatic, renal, or biliary routes.
Innovators Monograph
You find simplified version here Eptinezumab
